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Abstract: Bronchodilators represent the hallmark of symptomatic treatment of Chronic 
Obstructive Pulmonary Disease (COPD). There are four categories of bronchodilators: 
anticholinergics, methylxanthines, short-acting β2-agonists, and long-acting β2-agonists such 
as formoterol. Signiﬁ  cant research has been performed to investigate the efﬁ  cacy, safety and 
tolerability of formoterol in the therapeutic ﬁ  eld of COPD. Formoterol exhibits a rapid onset of 
bronchodilation similar to that observed with salbutamol, yet its long bronchodilatory duration is 
comparable to salmeterol. In addition, formoterol presents with a clear superiority in lung function 
improvement compared with either ipratropium bromide or oral theophylline, while its efﬁ  cacy 
improves when administered in combination with ipratropium. Formoterol has been shown to better 
reduce dynamic hyperinﬂ  ation, which is responsible for exercise intolerance and dyspnea in COPD 
patients, compared with other bronchodilators, whereas it exerts synergistic effect with tiotropium. 
Moreover, formoterol reduces exacerbations, increases days free of use of rescue medication and 
improves patients’ quality of life and disease symptoms. Formoterol has a favorable safety proﬁ  le 
and is better tolerated than theophylline. Collectively, data extracted from multicenter clinical 
trials support formoterol as a valid therapeutic option in the treatment of COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) affects more than 5% of the adult 
population and represents the fourth leading cause of death worldwide with a progres-
sively increasing mortality and morbidity (Murray and Lopez 1997; Coultas et al 2001). 
Approximately 2.75 million deaths per year are caused by COPD, and the number 
is expected to increase. It is estimated that by the year 2020 COPD will be the third-
leading cause of death and the ﬁ  fth leading cause of disability worldwide (Sullivan 
et al 2000; Michaud et al 2001). The traditional understanding of the pathogenesis of 
COPD has focused on the presence of chronic airﬂ  ow obstruction, which is slowly 
progressive and not fully reversible, and therefore the main therapeutic approach 
has been directed to relieve this. However, more recently it has been understood 
that airﬂ  ow limitation is associated with an abnormal inﬂ  ammatory response which 
appears to be responsible for the combination of small airway disease and architectural 
distortion of the lung parenchyma, the mucociliary dysfunction, and some systemic 
effects which include skeletal muscle dysfunction, nutritional abnormalities, weight 
loss, cardiovascular and nervous system abnormalities, and osteoskeletal effects such 
as osteoporosis (Oudijk et al 2003; Agusti 2005).
Spirometry provides the most common quantitative assessment of pulmonary 
function and is an essential tool in the diagnosis and monitoring of COPD. The most 
recent update of Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
(National Heart, Lung, and Blood Institute 2006) classiﬁ  es COPD severity into four 
groups according to spirometric results and proposes the proper treatment for each International Journal of COPD 2008:3(2) 206
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stage. Bronchodilators represent the hallmark of symptomatic 
treatment of COPD. There are four categories of broncho-
dilators: anticholinergics, methylxanthines, short-acting 
β2-agonists, and long-acting β2-agonists. As-needed use of 
a short-acting bronchodilator may be sufﬁ  cient for patients 
with mild disease (stage I), whereas treatment with a long 
acting bronchodilator or a combination may be necessary in 
moderate to severe disease (stages II-IV).
The current pharmacological therapy for COPD is lim-
ited in its ability to modify the progressive decline in lung 
function, a hallmark of COPD, and to reduce its mortality, 
which is associated with progressive disease, as was recently 
reported by the trial Towards a Revolution in COPD Health 
(TORCH) where the reduction in mortality failed to reach 
statistical signiﬁ  cance (Calverley et al 2007).
In the absence of available drugs preventing the evolu-
tion of the disease, the key aims for improving therapeutic 
outcomes are: to reduce symptoms, especially dyspnea, to 
improve exercise capacity, to reduce exacerbations and the 
possible need for hospitalization, and to enhance health status 
and improve quality of life (Mahler 2002). In line with these, 
experts state that the management of a stable COPD patient 
includes several clear steps: a) reduction of risk factor exposure 
by smoking cessation, b) optimizing expiratory ﬂ  ow by the 
use of bronchodilator drugs, such as long-acting β2-agonists 
(LABAs) including formoterol and salmeterol, and anticholin-
ergic agents such as tiotropium and ipratropium, c) reducing 
pulmonary inflammation most commonly by corticoste-
roids, and d) preventing and managing acute exacerbations 
(Calverley 2001; Sin et al 2003). In addition there is mounting 
evidence supporting the cardinal contribution of domiciliary 
oxygen treatment and pulmonary rehabilitation in ameliorating 
quality of life of patients developing exertional breathlessness. 
Surgical therapy (lung reduction for emphysematic patients) 
has a role in more advanced disease, whereas ventilatory sup-
port either acutely or chronically using non-invasive means 
has been studied and their utility in hypercapnic subjects has 
been clearly demonstrated (Plant et al 2000).
The scope of this review article is to summarize the 
current state of knowledge regarding the efﬁ  cacy, safety, 
and tolerability of inhaled formoterol in the management of 
COPD and present some of the future perspectives focused 
on quality of life, patient satisfaction and drug uptake.
Pharmacodynamic – 
pharmacokinetic properties
The pharmacologic properties of formoterol have been 
reviewed previously (Faulds et al 1991; Bartow and 
Brogden 1998). Brieﬂ  y, inhaled formoterol is a long-acting 
β2-agonist, with rapid onset (5 minutes in single- and 
multiple-dose studies) that maintains a bronchodilator 
effect for at least 12 hours. All β2-agonists are active on 
β2-adrenoreceptors of smooth muscles of the bronchi, 
resulting in their relaxation, and therefore their bron-
chodilation. β2-agonists also drastically inhibit systemic 
inﬂ  ammatory response or local cell proliferation (Johnson 
and Rennard 2001).
The pharmacodynamic effects of formoterol are medi-
ated through activation of intracellular adenyl cyclase, which 
catalyzes the conversion of ATP to cyclic adenosine mono-
phosphate (cAMPi) (Foradil 2004). All β2-agonists have the 
ability to increase heart rate and plasma glucose levels, and 
to cause hypokalemia by shifting potassium within cells. In 
addition these agents may increase levels of serum insulin, 
lactate acid, pyruvate acid, and free fatty acids when used 
in higher doses. In a double-blind placebo-controlled trial, 
Guhan et al (2000) showed dose-dependent increases in 
heart rate, corrected QT interval, and serum glucose levels, 
and dose-dependent decreases in plasma potassium con-
centrations with inhaled formoterol 24–96 μg or salmeterol 
100–400 μg.
The maximum plasma concentration of formoterol 
(92 ng/L) is reached within 5 minutes of inhalation of a 
single supraoptimal dose of it (120 μg). Urinary excretion 
ﬁ  ndings showed that the absorption in the lungs was linear 
with inhaled formoterol 12–96 μg in a study with 12 healthy 
volunteers. Moreover, in vitro plasma protein cleavage of 
formoterol was 61%–64% at concentrations 0.1–100 μg/L. 
Mean plasma concentrations of the drug at 10 minutes to 6 
hours post-inhalation are 4.0–8.8 ng/L and 8.0–17.3 ng/L, 
respectively, after multiple doses of formoterol 12–24 μg 
bid for a period of 12 weeks in COPD patients (Cazzola et al 
1994; Cheer and Scott 2002).
Formoterol is metabolized primarily in the liver by four 
cytochrome P450 (CYP) isoenzymes. These enzymes are not 
inhibited by the drug at therapeutic concentrations. Following 
inhalation of the drug in dose regimens of 12–24 μg by 18 
COPD patients, 7% of the overall dose was ﬁ  nally excreted 
in the urine as unchanged drug and 6%–9% of the total dose 
was cleaved as direct conjugates of formoterol. The mean 
terminal cleavage half-life was about 10 hours following 
inhalation of formoterol 120 μg by 12 healthy volunteers. 
Unfortunately, so far, there are no pharmacokinetic data for 
the use of formoterol in patients with hepatic or renal failure 
or impairment or in elderly individuals (Bartow and Brogden 
1998; Cheer and Scott 2002).International Journal of COPD 2008:3(2) 207
Formoterol for COPD
Efﬁ  cacy of the formoterol in COPD 
treatment
Improvement in lung function parameters
Formoterol, both as a pressurized metered dose inhaler 
(pMDI) or a dry powder inhaler (DPI) formulation, has 
demonstrated its efﬁ  cacy in the treatment of COPD and has 
been investigated in numerous clinical studies. These stud-
ies have examined single- or multiple-dose administration 
and have utilized a number of outcomes, which relate not 
only to lung function parameters, but also to symptoms, 
exacerbations, health-related quality of life (HRQoL), and 
exertion capacity. These outcomes have been considered in 
the context of primary, conﬁ  rmatory analyses (mainly FEV1), 
but also in the context of secondary exploratory analyses. As 
a word of caution, when multiple secondary outcomes are 
investigated, a random misleading result cannot be robustly 
excluded (Kottakis et al 2001; Friedman et al 2002).
Fast onset of bronchodilatory action
Kottakis et al (2002) compared formoterol 12 and 24 μg, as 
dry powder for oral inhalation, with dry powder salmeterol 
50 and 100 μg in a single-dose, cross-over study in patients 
with partially reversible, moderately severe, stable COPD; 
ΔFEV1 following a standard dose of salbutamol was not in 
excess of 12% of patient’s predicted normal value. Median 
time to a 12% change from baseline FEV1 value was 5 min 
with both formoterol doses and 10 min with both salmeterol 
doses. This was in line with data generated in asthma studies 
that support a fast action comparable to that of salbutamol 
(Donohue 2004). In fact, Benhamou et al (2001) blindly com-
pared the administration of 24 μg dry powder of formoterol 
in a single dose with 400 μg dry powder salbutamol in 
patients with severe COPD. Both active drugs demonstrated 
their fast onset of effect on FEV1 in this patient population, 
both drugs producing similar bronchodilation within 5 min 
of dosing and during the ensuing 30 min. Improvement in 
FEV1 from 5 min to 3 hours post-treatment was also similar 
with formoterol and salbutamol. Both drugs induced almost 
maximal bronchodilation by 30 min post-treatment, 80% of 
maximum effect occurring within 5 min.
This result was further corroborated in the study by 
Maesen et al (1999) in which single doses of 6 and 24 μg dry 
powder formoterol administered to poorly reversible COPD 
patients resulted in a modest increase in FEV1. However, 
signiﬁ  cant improvement, compared to placebo, was observed
in the work of breathing (WoB) (25%) and airway 
resistance (Raw) (20%) within 10 min.
Long duration of bronchodilatory action
In the same study (Maesen et al 1999) the FEV1 remained 
higher during the 12 post-dose hours after formoterol, com-
pared with placebo. For the area under the FEV1 curve (AUC) 
0–12 hours post dose, a mean increase in FEV1 of 50 mL 
was calculated for placebo, 120 mL for 6 μg and 230 mL for 
the 24 μg formoterol. These results over the 12-hour dosing 
interval may be considered as clinically important in a patient 
population with stable, poorly reversible COPD, as they 
exceed 100 mL for the 6 μg dose and the upper limit of the 
daily variability of the measurement for the 24 μg dose.
Only two studies have examined so far the effect of for-
moterol administered in multiple doses. Rossi et al (2002) 
compared 12 and 24 μg of formoterol given bid in patients 
with stable COPD, versus oral sustained-release theophyl-
line bid; Dahl et al (2001) compared the same dosage of 
formoterol (12 and 24 μg bid) with 40 μg ipratropium bro-
mide qid. Both studies were of a parallel group design with 
each patient receiving treatment for 12 months and 3 months, 
respectively. Both studies utilized a group of patients receiv-
ing placebo (ie, usual therapy) to facilitate the analyses. Both 
studies demonstrated 12 hours of bronchodilatory action that 
was signiﬁ  cant and clinically meaningful over placebo and 
active comparators, and persisted over time.
Formoterol versus placebo
The vast majority of clinical studies have considered the 
effect of formoterol on FEV1. These studies have, in most 
situations, utilized this marker of efﬁ  cacy as the primary 
outcome, for which each corresponding study was powered. 
For a disease characterized by a relative ﬁ  xed airﬂ  ow obstruc-
tion, the utilization of FEV1 to test for efﬁ  cacy requires the 
inclusion of patients with at least some degree of FEV1 revers-
ibility. Therefore in these studies (Benhamou et al 2001; 
Kottakis et al 2002) an upper limit of FEV1 change of not 
less than 12% of patent’s predicted normal and a minimum 
of at least 5% of patient’s baseline value following a standard 
dose of a short acting β2-agonist was often used; other limits 
though have also been used (Maesen et al 1999; van Noord 
et al 2005). Resting lung volumes and capacities, especially 
those that predict the effect on dynamic hyperinﬂ  ation, 
have also been used in a number of studies, as secondary 
efﬁ  cacy outcomes (Bouros et al 2004; Di Marco et al 2006; 
van Noord 2006).
Three multicenter, randomized, placebo-controlled 
studies are currently evaluating the effect of formoterol on 
dynamic hyperinﬂ  ation, a factor that often contributes to dys-
pnea and exercise intolerance in COPD patients. In addition International Journal of COPD 2008:3(2) 208
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to FVC and FEV1, indices related to dynamic hyperinﬂ  ation 
such as inspiratory capacity (IC) are both reproducible and 
well correlated with exercise tolerance and dyspnea (Yan et al 
1997). Di Marco and colleagues (2003) compared the acute 
effect of 4 inhaled bronchodilators, including formoterol, and 
placebo on IC, FEV1, FVC, and dyspnea in 20 consecutive 
COPD patients. Patients underwent lung function tests and 
dyspnea evaluation at baseline and at 5 serial time points after 
drug or placebo administration. Results clearly demonstrated 
that patients with decreased baseline IC showed a statistically 
signiﬁ  cant increase of IC, especially at 30 mins post-bron-
chodilation, which was highly correlated with improvement 
in dyspnea sensation at rest.
Formoterol versus other β2-agonists
D’Urzo et al (2001) compared the addition of formoterol 
12 μg bid to the addition of salbutamol 200 μg qid in COPD 
patients on ipratropium 40 μg qid. In this investigation a 
randomized double blind 2-period cross-over design was 
employed, with every patient treated for 3 weeks during 
each of the two treatment periods. Randomized patients 
presented with a limited reversibility of their airﬂ  ow obstruc-
tion, of less than 200 mL following a standard salbutamol 
dose. The results showed that morning peak expiratory 
ﬂ  ow (PEF) and FEV1 were signiﬁ  cantly higher with the 
formoterol–ipratropium co-treatment compared with the 
salbutamol–ipratropium combination. Similar beneﬁ  cial 
ﬁ  ndings were noted in the symptom score, the percentage of 
days free of rescue drug, and the health status.
The impact of formoterol (12 μg) on IC in comparison with 
salmeterol (50 μg) was studied in 47 COPD patients (Bouros 
et al 2004). Findings further extended the superiority of for-
moterol compared with salmeterol in acutely improving (over 
the ﬁ  rst hour post-dose) indices of dynamic hyperinﬂ  ation in 
COPD patients with low baseline IC, an observation in line with 
the faster onset of bronchodilation exhibited by formoterol.
Vervloet et al (1998) conducted a 6-month study in 482 
COPD patients on regular treatment with inhaled cortico-
steroids (ICS). Patients received either formoterol 12 μg 
bid or salmeterol 50 μg bid. Improvements in morning 
predose PEF were similar in both groups while patients on 
formoterol experienced superior improvements in evening 
predose PEF rates.
Formoterol versus anticholinergics
Ipratropium
Sichletidis et al (1999) compared the bronchodilatory 
responses to formoterol 12 μg and 24 μg versus ipratropium 
bromide 40 μg and their combination in 27 patients with 
COPD. Intriguingly, effects of formoterol in FEV1 were 
similar to the combination of the two agents and highly 
superior to ipratropium alone.
Two years later, Dahl et al (2001) clearly demonstrated 
in a large series of 780 patients that formoterol (12 and 24 μg 
bid) had faster onset and longer duration of action than 
ipratropium bromide (40 μg qid) and was more effective in 
terms of increases in FEV1, reductions in symptoms scores, 
and improvements in health status and exacerbations over a 
12-week treatment period.
Tiotropium
Cazzola et al (2004) looked for an additive effect between 
tiotropium and formoterol in a double-blind and double-
dummy, single-dose, cross-over clinical study, in 20 
patients with stable COPD. Tested were single doses of 
12 μg formoterol, 18 μg tiotropium, and the combina-
tion of these doses. Changes in FEV1 10 minutes after 
inhalation were statistically greater with formoterol than 
with tiotropium. At the same time point, combination of 
formoterol – tiotropium was also superior to tiotropium 
alone, but not to formoterol alone. Rise in FEV1 was 
achieved in 38 minutes by formoterol versus 79 minutes 
by tiotropium. For maximum increase in mean FEV1, arith-
metic differences in favor of the combination of the two 
bronchodilators failed to achieve statistical signiﬁ  cance 
versus the monotherapies (0.192 L for formoterol, 0.176 L 
for tiotropium, 0.210 L for the combination). No statistical 
signiﬁ  cance was observed in average FEV1. However, at 
24 hours the mean FEV1 value was still statistically signiﬁ  -
cantly higher than the pre-dosing value following tiotropium 
and the combination, but not with formoterol alone (0.084 
L after tiotropium, 0.088 L after tiotropium + formoterol, 
0.058 L after formoterol alone).
The statistical signiﬁ  cance that was not achieved in the 
Cazzola et al single dose study, was shown in a multiple dose, 
3-way cross-over study in stable COPD patients, 2 weeks 
duration per treatment period, by Van Noord et al (2006). In 
this study, monotherapy with tiotropium was compared with 
combinations of tiotropium plus formoterol once, or twice 
daily. The addition of formoterol was superior to tiotropium 
alone in average FEV1 during the 24-hour period. Addition-
ally, authors showed that the add-on formoterol dose of 12 μg 
in patients receiving tiotropium improved resting IC as well 
as in FVC and FEV1 for more than 12 hours. Addition of a 
second dose of formoterol further increased IC and FVC for 
a time period that did not exceed 12 hours.International Journal of COPD 2008:3(2) 209
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Di Marco et al (2006) investigated the effect of single 
doses of formoterol (12 μg), tiotropium (18 μg), and their 
combination in 21 patients experiencing an acute exacer-
bation of COPD. Differences in peak FEV1 and FVC, and 
24-hour average FEV1 and FVC were not recorded between 
the monotherapies, with the combination of the two achiev-
ing a signiﬁ  cant advantage over the monotherapies. More 
important, a bronchodilating action was evident at 24 hours 
only with the combination of the two bronchodilators.
Formoterol versus theophylline
In the study by Rossi et al (2002), formoterol (12 μg bid) was 
found to improve statistically FEV1 AUC at 3 and 12 months. 
This beneﬁ  cial effect was also observed with formoterol 
24 μg twice daily after 3 months. Both doses were superior 
to theophylline for FVC AUC at 3 months.
Improvement in symptoms and the need 
for rescue medication
The published guidelines of the Global Initiative for COPD 
recommend that bronchodilator medications be prescribed 
to COPD patients for relief of symptoms (National Heart, 
Lung, and Blood Institute 2006). The classic symptoms of 
COPD are chronic cough, excessive sputum production, and 
dyspnea, which is the main reason for consultation with the 
primary care physician and a major cause of disability and 
anxiety (Mahler 2002). Although, FEV1 has been widely 
used as a surrogate marker for dyspnea, many studies have 
documented ameliorations in dyspnea without any accom-
panying spirometry improvement (Guyatt et al 1987, 1989; 
Mahler et al 1995).
Dahl et al (2001) performed a multicenter, double blind, 
randomized placebo-controlled study and compared the efﬁ  -
cacy of formoterol and ipratropium bromide in 740 COPD 
patients by assessing disease symptoms with a patient diary 
that recorded the use of rescue medication and a series of 
6 parameters on a 4-point scale. Symptoms that were evaluated 
included ability to perform usual daily activity, breathlessness 
over the previous 24 hours and on rising, night awakenings due 
to respiratory symptoms, and cough and sputum production. 
In contrast to ipratropium, both doses of formoterol (12 and 
24 μg) signiﬁ  cantly improved symptom scores and signiﬁ  cantly 
reduced the use of rescue drugs compared with placebo over a 
12-week period. Results were substantiated by Campbell et al 
in a study evaluating the efﬁ  cacy and tolerability of formoterol 
compared to placebo, using as primary endpoints lung function 
parameters and COPD symptoms (Campbell et al 2005). The 
overall treatment period represents the most important caveat 
of this study due to the fact that it may be considered too short 
to capture a signiﬁ  cant number of disease deteriorations and 
to evaluate parameters such as daily symptoms and rescue use 
that need to be addressed on a longitudinal basis.
With this aim in mind, Rossi et al (2002) used a similar 
patient diary with the same six parameters to evaluate the 
effectiveness of formoterol (12 and 24 μg) compared with 
oral theophylline or placebo in improving daily symptoms 
over a 12-month treatment period. Although symptom scores 
at 3-month intervals tended to be lower in patients receiving 
formoterol 12 or 24 μg than in the placebo group, differences 
failed to reach statistical signiﬁ  cance. A type II error cannot 
be excluded; however, the exact reason for this discrepancy 
remains unknown. Furthermore, authors reported that both 
formoterol doses, compared with the placebo group, exhib-
ited signiﬁ  cant decrement in the mean number of puffs of 
rescue medication and increment in the percentage of days 
free of rescue drug over the entire treatment period.
In the study by D’Urzo et al (2001) COPD patients 
receiving ipratropium 40 μg qid reported lower scores in 
symptoms such as coughing, breathlessness, and sputum 
production when formoterol 12 μg × 2 was added instead 
of salbutamol 200 μg × 4. Moreover, formoterol instead of 
salbutamol resulted in fewer puffs/day of rescue medicine, 
and more days with no use of rescue drug.
Improvement in COPD exacerbations
In the study by Rossi et al (2002), which compared the efﬁ  -
cacy of formoterol versus theophylline or placebo, formoterol 
(either 12 μg or 24 μg daily) was superior in preventing mild 
exacerbations. Daily use of 24 μg of formoterol resulted in 
statistically less need for additional therapy (antibiotics, 
corticosteroids, or oxygen). The need for COPD-related 
hospitalization was observed to be 4 times higher in the pla-
cebo group compared with the formoterol 24 mg group, and 
2 times higher in the 12 mg group. These results conﬁ  rmed 
those by Dahl et al (2001) which showed that frequency of 
mild exacerbations was signiﬁ  cantly lower in patients with 
formoterol versus placebo.
Formoterol seems to be superior to salbutamol for COPD 
exacerbations, since more patients denied having exacerba-
tions (D’Urzo et al 2001). Even mild exacerbations (‘bad 
days’) were less in this group.
Improvement in health-related quality 
of life (HRQoL)
One of the major clinical outcomes measured in evaluating 
the responses to pharmacotherapy in patients with COPD International Journal of COPD 2008:3(2) 210
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include health status. The Chronic Respiratory Disease Ques-
tionnaire (Guyatt et al 1987) and the St George’s Respiratory 
Questionnaire (SGRQ) (Jones et al 1992), speciﬁ  c measure-
ment tools used widely in multicenter clinical trials with 
the disease, are the best and most reliable ways of record-
ing treatment response. In addition, the generic Medical 
Outcomes Short Form-36 (SF-36) questionnaire (Ware 
et al 1992) can reﬂ  ect changes in HRQoL among patients 
receiving therapy.
SGRQ was used as a secondary efﬁ  cacy variable in all 
the aforementioned large multicenter studies. A change of 
4 points from baseline was considered statistically signiﬁ  -
cant, indicating an important difference for the patient. The 
questionnaire was administered before the ﬁ  rst dose of the 
study and at the end of the treatment period. In the study 
by Dahl et al (2001), COPD patients received a beneﬁ  cial 
effect for SGRQ total score with both formoterol dose 
regimens (12 and 24 μg). These patients also had also 
statistically and clinically signiﬁ  cant improvements in the 
symptoms, activity, and impacts domains, as mentioned 
above. The latter results were further extended in the other 
multicenter clinical trial by Rossi et al (2002) and beneﬁ  cial 
effect was sustained over a longer treatment period of time 
(12 months).
The above observations give credence to the view that 
LABAs, including formoterol, not only improve lung func-
tion by relaxing bronchial smooth muscle but may also 
provide clinical beneﬁ  ts that can be proven cardinal to 
symptomatic COPD patients.
Improvement in inﬂ  ammatory markers
COPD is associated with chronic inﬂ  ammatory response 
in the lungs. Elevation of neutrophil count is detected in 
sputum, and of macrophage count in lung parenchyma 
and in bronchoalveolar lavage (National Heart, Lung, and 
Blood Institute 2006). Increased CD4+ and CD8+ cell 
counts and an elevation of CD8+:CD4+ ratio are also 
observed. Additionaly, B-lymphocytes are increased, 
along with epithelial cells, and eosinophils. The latter is 
detected during exacerbations (National Heart, Lung, and 
Blood Institute 2006).
Animal experimental models for COPD have demon-
strated that long acting β2-agonists inﬂ  uence neutrophil 
count and function (Johnson and Rennard 2001) while 
Bowden et al (1994) showed formoterol to be effective in 
inhibiting neutrophil adhesion in the airway mucosa of the 
rats. In other studies performed in vitro, formoterol has 
inhibited activated neutrophil oxidant generation (Anderson 
et al 1996), leucotriene release (Rabe et al 1993), and 
superoxide anion generation (Okada et al 1993) from guinea 
pig eosinophils.
Efﬁ  cacy of combination with inhaled 
steroids therapy
The synergistic effect of ICS combined with long-acting 
β2-agonists has been suggested for COPD as well as for 
asthma. Two ﬁ  xed combinations are currently available: 
salmeterol–ﬂ  uticasone and formoterol – budesonide. The 
current management guidelines (National Heart, Lung, 
and Blood Institute 2006) recommend addition of an ICS 
to bronchodilator therapy for COPD patients with an FEV1 
50% predicted, who experience repeated exacerbations. No 
important difference between the two combinations in the 
recommended dosages was reported by Cazzola et al (2003) 
in patients with COPD.
In a 12-month, randomized, double-blind, placebo-
controlled, parallel study, the combination of formoterol 
with budesonide (formoterol 6 μg – budesonide 200 μg) 
administration was compared with that of the individual 
agents (formoterol 6 μg, budesonide 200 μg) and of placebo 
in terms of efﬁ  cacy and safety (Szafranski et al 2003). Medi-
cation was administered via two inhalations twice daily. The 
aim of this study was to examine the efﬁ  cacy and safety of 
the combination of formoterol/ budesonide against placebo 
and monocomponents in terms of FEV1 changes and numbers 
of exacerbations. In addition, other parameters such as FVC, 
PEF, HRQoL, symptoms, and use of relieve medication 
were recorded. This study concluded that the combination 
of the two agents increased FEV1 by 15% vs placebo, and 
1% vs. formoterol alone; and reduced by 24% the number of 
exacerbations vs placebo. Also impressive were the effects 
of formeterol  – budesonide combination vs placebo on the 
number of exacerbations, total symptom score, days free of 
shortness of breath, nights free of awakenings, use of reliever 
medication, and HRQoL scores.
A related trial by Calverley et al (2003) studied the 
maintenance of clinical improvement over a longer period in 
COPD patients under inhaled therapy and investigated which 
drugs were responsible for patients well being. The primary 
outcomes were time to ﬁ  rst exacerbation and change in FEV1. 
This study demonstrated that the combination of formoterol 
and budesonide provided effective maintenance therapy over 
12 months. A reduced withdrawal in the combination therapy 
group, due to worsening of COPD, than in the monotherapy 
groups was recorded. Combination treatment also prolonged 
the time to ﬁ  rst COPD exacerbation and signiﬁ  cantly improved International Journal of COPD 2008:3(2) 211
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SGRQ total scores and use of rescue medications compared 
with monotherapy with formoterol or budesonide.
Safety and tolerability
Long-acting β2-agonists are generally considered to be well 
tolerated, and a low incidence of adverse events has been 
reported across all the clinical studies conducted (Table 1). 
A wide clinical experience has been gained on the use of 
formoterol in patients with asthma. In some of these studies, 
formoterol has been evaluated at doses higher than thera-
peutic, showing a good safety proﬁ  le. It has been however 
important to evaluate whether the agent is also safe in COPD 
patients, in light of possible complicating factors such as age 
and concomitant disorders.
In a study by Dahl et al (2002) comparing the efﬁ  cacy and 
safety of formoterol at doses of 12 μg (F12) and 24 μg (F24) 
twice daily versus placebo and ipratropium bromide in 780 
COPD patients over a 12-week treatment period, the incidence 
of adverse events was similar in all the treatment groups, as 
well as the proportion of patients reporting adverse events 
considered drug-related by the investigator (11% on 12 μg, 
19% on 24 μg, 12% on placebo and 12% on ipratropium). 
The most frequent drug-related adverse events were headache, 
tremor, dry mouth, muscle cramps, coughing, COPD exacerba-
tions, dyspnea, and pruritus. Cardiovascular events and heart 
rhythm disorders were uncommon across all the treatment 
groups (respectively, 1 and 6 on 12 μg, 2 and 4 on 24 μg, 5 
and 8 on placebo, and 5 and 8 on ipratropium). There was a 
low incidence of clinically relevant abnormal serum potassium 
and glucose, with no difference among treatment groups, but 
most importantly no deaths were recorded in this study.
In this respect, the safety of formoterol use as mono-
therapy in COPD patients has been good in all clinical trials 
conducted compared with placebo, ipratropium, and other 
β2-agonists and formoterol were better tolerated than the-
ophylline. Only a small proportion of patients experienced 
signiﬁ  cant systemic adverse reactions.
In the study of Aalbers et al (2002) 3 different doses of 
formoterol DPI (4.5–9–18 μg twice daily) and placebo were 
administered to 690 patients with COPD during a 12-week 
treatment period. The most commonly reported adverse 
events were deterioration of COPD and respiratory infec-
tions, both present with a similar incidence in all the treat-
ment groups (including placebo). No other adverse events 
occurred in 5% of patients.
Results of a 6-month safety and efﬁ  cacy comparison of 
formoterol and salmeterol (Vervloet et al 1998) reported 
that both drugs were well tolerated and that adverse events 
were in similar proportions in both treatment groups. 
However, salmeterol has been associated with airway hyper-
responsiveness (Sears 2002) and deterioration of lung func-
tion in children with asthma (Verberne et al 1997).
Similar ﬁ  ndings were obtained in the study of Rossi et al 
(26) evaluating the efﬁ  cacy and safety of formoterol at the 
doses of 12 μg and 24 μg twice daily versus placebo and 
oral slow-release theophylline in 854 COPD patients during 
a 12 months’ treatment. The most common adverse events 
occurred with a similar incidence in all treatment groups 
(including placebo). The incidence of adverse events con-
sidered as drug-related by the investigator, was similar in the 
12 μg and 24 μg formoterol and in the placebo groups (9% on 
F12, 8% on F24 and 8% on placebo), and higher in patients 
treated with oral slow-release theophylline (32%).
Discontinuations due to adverse events (COPD-related 
and not COPD-related) were from 2- to 4-fold more frequent 
in patients treated with theophylline, compared with the other 
groups. Four deaths occurred in the study (3 on 12 μg and 
1 on 24 μg); however, only one case (myocardial infarction 
with rupture of the interventricular cardiac septum) was 
considered possibly related to study drug, while the others 
were considered not related to study drug (1 suicide, 1 post-
traumatic death, 1 possible myocardial infarction).
In two other studies in which formoterol was adminis-
tered at 9 μg bid (corresponding to a metered dose of 12 μg 
bid) in comparison with placebo, budesonide, and the ﬁ  xed 
combination budesonide – formoterol for 12 months, the 
safety proﬁ  le was similar to what previously known (Cal-
verley et al 2003; Szafranski et al 2003). No further safety 
issues were noticed while the most commonly reported 
adverse events were deterioration of COPD and respiratory 
infection. The number of serious adverse events and deaths 
in the two studies did not show a relevant treatment-related 
pattern. Tachycardia and tremor, known as class effects of 
β2-agonists, were reported in a very low proportion of patients 
(15%–3%) with no evident dose relationship.
Discussion
According to Global Initiative for COPD (National Heart, 
Lung, and Blood Institute 2006), long-acting bronchodilators 
are central to symptom management in COPD, are prescribed 
on an as-needed or on a regular basis to prevent or to reduce 
symptoms, and are convenient and effective, whereas their 
combination may improve efﬁ  cacy and reduce side effects 
compared with increasing the dose of a single bronchodila-
tor. Recent clinical trials attribute the impact of formoterol 
in the treatment of COPD mainly to the distinctive, rapid International Journal of COPD 2008:3(2) 212
Steiropoulos et al
T
a
b
l
e
 
1
 
M
o
s
t
 
c
o
m
m
o
n
l
y
 
r
e
p
o
r
t
e
d
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
F
o
r
m
o
t
e
r
o
l
4
.
5
 
μ
g
9
 
μ
g
1
2
 
μ
g
1
8
 
μ
g
2
4
μ
g
p
l
a
c
e
b
o
A
u
t
h
o
r
A
a
l
b
e
r
s
 
e
t
 
a
l
 
2
0
0
2
C
a
l
v
e
r
l
e
y
 
e
t
 
a
l
 
2
0
0
3
A
a
l
b
e
r
s
 
e
t
 
a
l
 
2
0
0
2
C
a
l
v
e
r
l
e
y
 
e
t
 
a
l
 
2
0
0
3
R
o
s
s
i
 
e
t
 
a
l
 
2
0
0
2
A
a
l
b
e
r
s
 
e
t
 
a
l
 
2
0
0
2
C
a
l
v
e
r
l
e
y
 
e
t
 
a
l
 
2
0
0
3
R
o
s
s
i
 
e
t
 
a
l
 
2
0
0
2
A
a
l
b
e
r
s
 
e
t
 
a
l
 
2
0
0
2
C
a
l
v
e
r
l
e
y
 
e
t
 
a
l
 
2
0
0
3
R
o
s
s
i
 
e
t
 
a
l
 
2
0
0
2
S
u
b
j
e
c
t
s
 
n
1
7
1
2
5
5
1
6
9
2
5
7
2
1
1
1
7
8
2
5
4
2
1
4
1
7
4
2
5
6
2
2
0
D
e
t
e
r
i
o
r
a
t
i
o
n
 
o
f
 
C
O
P
D
7
 
(
4
)
N
A
1
2
 
(
7
)
N
A
N
A
1
8
 
(
1
0
)
N
A
N
A
1
6
 
(
9
)
N
A
N
A
R
e
s
p
i
r
a
t
o
r
y
 
i
n
f
e
c
t
i
o
n
2
1
 
(
1
2
)
3
3
 
(
1
3
)
2
4
 
(
1
4
)
3
4
 
(
1
3
)
N
A
1
7
 
(
1
0
)
3
6
 
(
1
4
)
N
A
1
8
 
(
1
0
)
2
4
 
(
9
)
N
A
C
h
e
s
t
 
p
a
i
n
1
 
(
1
)
6
(
2
)
2
 
(
1
)
4
 
(
2
)
N
A
5
 
(
3
)
8
 
(
3
)
N
A
2
 
(
1
)
5
 
(
2
)
N
A
B
a
c
k
 
p
a
i
n
1
 
(
1
)
6
(
2
)
4
 
(
2
)
4
 
(
2
)
N
A
4
 
(
2
)
8
 
(
3
)
N
A
3
 
(
2
)
7
 
(
3
)
N
A
H
e
a
d
a
c
h
e
4
 
(
2
)
N
A
3
 
(
2
)
N
A
1
3
 
(
6
)
4
 
(
2
)
N
A
8
 
(
4
)
8
 
(
5
)
N
A
2
0
 
(
9
)
H
y
p
e
r
g
l
y
c
e
m
i
a
N
A
N
A
2
 
(
1
)
N
A
N
A
3
 
(
2
)
N
A
N
A
N
A
N
A
N
A
H
y
p
e
r
t
e
n
s
i
o
n
N
A
N
A
3
 
(
2
)
N
A
N
A
3
 
(
2
)
N
A
N
A
3
 
(
2
)
N
A
N
A
P
a
i
n
9
 
(
5
)
1
 
(
1
)
N
A
N
A
3
 
(
2
)
N
A
N
A
2
 
(
1
)
N
A
N
A
P
h
a
r
y
n
g
i
t
i
s
3
 
(
2
)
8
(
3
)
5
 
(
3
)
5
 
(
2
)
N
A
3
 
(
2
)
7
 
(
3
)
N
A
4
 
(
2
)
5
 
(
2
)
N
A
T
a
c
h
y
c
a
r
d
i
a
N
A
N
A
5
 
(
3
)
N
A
N
A
3
 
(
2
)
N
A
N
A
N
A
N
A
N
A
T
r
e
m
o
r
1
 
(
1
)
1
 
(
1
)
N
A
1
 
(
1
)
3
 
(
2
)
N
A
4
 
(
2
)
N
A
N
A
2
 
(
1
)
F
e
v
e
r
N
A
1
1
(
4
)
N
A
9
 
(
4
)
N
A
N
A
3
6
 
(
1
4
)
N
A
2
 
(
1
)
N
A
D
y
s
p
n
e
a
N
A
1
2
(
5
)
N
A
5
 
(
2
)
1
2
 
(
6
)
N
A
5
 
(
2
)
1
3
 
(
6
)
N
A
5
 
(
2
)
1
1
 
(
5
)
P
n
e
u
m
o
n
i
a
N
A
7
(
3
)
N
A
5
 
(
2
)
N
A
N
A
8
 
(
3
)
N
A
N
A
2
 
(
1
)
N
A
R
h
i
n
i
t
i
s
N
A
6
(
2
)
N
A
3
 
(
1
)
N
A
N
A
1
1
 
(
4
)
N
A
N
A
1
 
(

0
.
5
)
N
A
D
y
s
p
h
o
n
i
a
N
A
1
(

0
.
5
)
N
A
5
 
(
2
)
N
A
N
A
5
 
(
2
)
N
A
N
A
1
 
(
0
.
5
)
N
A
M
o
n
i
l
i
a
s
i
s
N
A
2
(
1
)
N
A
4
 
(
2
)
N
A
N
A
4
 
(
2
)
N
A
N
A
N
A
N
A
V
i
r
a
l
 
I
n
f
e
c
t
i
o
n
N
A
N
A
N
A
N
A
3
4
 
(
1
6
)
N
A
N
A
3
1
 
(
1
5
)
N
A
N
A
3
9
 
(
1
8
)
C
O
P
D
 
E
x
a
c
e
r
b
a
t
i
o
n
N
A
N
A
N
A
N
A
3
4
 
(
1
6
)
N
A
N
A
2
6
 
(
1
2
)
N
A
N
A
3
3
 
(
1
5
)
B
r
o
n
c
h
i
t
i
s
N
A
N
A
N
A
N
A
2
1
 
(
1
0
)
N
A
N
A
2
1
 
(
1
0
)
N
A
N
A
2
0
 
(
9
)
U
R
T
I
N
A
N
A
N
A
N
A
2
0
 
(
1
0
)
N
A
N
A
1
4
 
(
7
)
N
A
N
A
1
6
 
(
7
)
I
n
s
o
m
n
i
a
N
A
N
A
N
A
N
A
3
 
(
1
)
N
A
N
A
1
 
(
1
)
N
A
N
A
5
 
(
2
)
D
y
s
p
e
p
s
i
a
N
A
N
A
N
A
N
A
2
 
(
1
)
N
A
N
A
3
 
(
1
)
N
A
N
A
3
 
(
1
)
A
b
d
o
m
i
n
a
l
 
p
a
i
n
N
A
N
A
N
A
N
A
1
 
(
1
)
N
A
N
A
8
 
(
4
)
N
A
N
A
9
 
(
4
)
N
a
u
s
e
a
N
A
N
A
N
A
N
A
1
 
(
1
)
N
A
N
A
1
 
(
1
)
N
A
N
A
4
 
(
2
)
V
o
m
i
t
i
n
g
N
A
N
A
N
A
N
A
1
 
(
1
)
N
A
N
A
1
 
(
1
)
N
A
N
A
N
A
N
o
t
e
:
 
d
a
t
a
 
a
r
e
 
p
r
e
s
e
n
t
e
d
 
a
s
 
n
u
m
b
e
r
 
o
f
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
w
i
t
h
 
%
 
o
f
 
p
a
t
i
e
n
t
s
 
r
e
p
o
r
t
i
n
g
 
i
n
 
p
a
r
e
n
t
h
e
s
e
s
.
A
b
b
r
e
v
i
a
t
i
o
n
:
 
U
R
T
I
,
 
u
p
p
e
r
 
r
e
s
p
i
r
a
t
o
r
y
 
t
r
a
c
t
 
i
n
f
e
c
t
i
o
n
.International Journal of COPD 2008:3(2) 213
Formoterol for COPD
onset, long-acting β2-adrenoreceptor activity. Formoterol 
produces signiﬁ  cant improvements within 5 minutes and 
these beneﬁ  ts are sustained for almost half of the day. It 
has a more rapid onset and longer duration of action than 
ipratropium bromide, and has clear superiority in terms of 
lung function and quality of life.
Furthermore, it provides signiﬁ  cantly greater improve-
ments in symptom control and need for reliever medication 
than ipratropium bromide. Formoterol is more effective than 
theophylline in reducing the number of COPD exacerbations 
and increasing the number of days without rescue medica-
tion, and is better tolerated. Data presented and reviewed in 
this paper support the notion that formoterol has therapeutic 
and safety proﬁ  les comparable to and sometimes superior 
even to those of current ﬁ  rst-line agents for moderate COPD 
(Table 2). These results not only support its use as a ﬁ  rst-line 
THEO 200 mg 
BID
THEO 300 mg 
BID
PL
Di Marco et al 2003 20 65 F 12 μg
ALB 200 μg
SLM 50 μg
OXITR 200 μg
PL
Bouros et al 2004 47 63.5 F 12 μg
F 24 μg
SLM 50 μg
SLM 100 μg
PL
Cazzola et al 2004 20 70.7 F 12 μg
TIO 18 μg
F 12 μg + TIO 
18 μg
Campbell et al 2005 657 60 F 9 μg 
BID + TER 0.5 
mg prn
F 9 μg BID + F 
4.5 μg prn
PL + TER 
0.5 mg prn
Di Marco et al 2006 21 72 F 12 μg BID
TIO 18 μg QID
F 12 μg 
BID + TIO 
18 μg QID
Abbreviations: BID, twice daily; F, formoterol; IPR, ipratropium; OXITR, oxitropium, 
QID, 4 times daily; PL, placebo, SLM, salmeterol; TER, terbutaline; THEO, theophylline; 
TIO, tiotropium.
Author Patients
enrolled
Mean age
(years)
Treatment
Table 2 (Continued) Table 2 Clinical trials on formoterol in COPD patients
Author Patients
enrolled
Mean age
(years)
Treatment
Cazzola et al 1994 16 64.3 F 24 μg
SLM 50 μg
ALB 200 μg
PL
Cazzola et al 1995 12 62.5 F 12 μg
F24 μg
SLM 50 μg
Vervloet et al 1998 482 48 F 12 μg BID
SLM 50 μg BID
Celik et al 1999 22 57.3 F 12 μg
SLM 50 μg
PL
Maesen et al 1999 12 61 F 6 μg
F 24 μg
PL
Sichletidis et al 1999 27 64.7 F 12 μg
F 24 μg
IPR 40 μg
IPR 80 μg
F 12 μg + IPR 
40 μg
PL
Benhamou et al 2001 24 61.6 ± 7.8 F 24 μg
ALB 400 μg
PL
Cazzola et al 2001 16 65.6 F 12 μg
F 24 μg
ALB 400 μg
ALB 800 μg
PL
Dahl et al 2001 780 63.7 F 12 μg BID
F 24 μg BID
IPR 40 μg QID
PL
D’Urzo et al 2001 159 65 F 12 μg 
BID + IPR 
40 μg QID
SLM 
200 μg + IPR 
40 μg QID
Aalbers et al 2002 692 62.4 F 4.5 μg BID
F 9 μg BID
F 18 μg BID
PL
Cazzola et al 2002 20 60.6 F 9 μg
ALB 100 μg
F 18 μg
ALB 200 μg
Kottakis et al 2002 47 63.5 F 12 μg
F 24 μg
SLM 50 μg
SLM 100 μg
PL
Rossi et al 2002 854 63 F 12 μg BID
F 24 μg BID
(Continued)International Journal of COPD 2008:3(2) 214
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therapy in COPD but also give credence to its administration 
in combination with ipratropium bromide in patients who 
are non-responders to a single bronchodilator.
Finally, although formoterol is not yet indicated for 
administration on an as-needed basis for patients with 
mild disease, its rapid onset of action coupled with data 
derived from a clinical trial (Cazzola et al 2001) support 
its “on-demand” use, indicating it as a promising candidate 
for patients suffering from acute exacerbations of partially 
reversible COPD.
In conclusion, most studies reviewed in this paper have 
shown that formoterol has beneﬁ  cial efﬁ  cacy, safety, and 
tolerability proﬁ  les when administered in patients with 
COPD. Data extracted from multicenter clinical trials 
support formoterol as a valid therapeutic option in the 
treatment of COPD. Therefore, ﬁ  ndings from the above 
studies need to be taken into consideration for future 
updates of guidelines for the management and treatment 
of this dismal disease.
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